Phosphorylation-dependent interaction between antigenic peptides and MHC class I: A molecular basis for the presentation of transformed self

Nature Immunology

Volumn 9, Issue 11, 2008, Pages 1236-1243

  Mohammed, Fiyaz ^a   Cobbold, Mark ^a,b   Zarling, Angela L ^b   Salim, Mahboob ^a   Barrett Wilt, Gregory A ^c   Shabanowitz, Jeffrey ^c   Hunt, Donald F ^c   Engelhard, Victor H ^b   Willcox, Benjamin E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOPEPTIDE;

ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HLA-A ANTIGENS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 54549089744     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1660     Document Type: Article

References (40)

1. Rock, K.L. & Goldberg, A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17, 739-779 (1999).
2. Engelhard, V.H., Altrich-Vanlith, M., Ostankovitch, M. & Zarling, A.L. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 18, 92-97 (2006).
3. Zarling, A.L. et al. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 192, 1755-1762 (2000).
4. Zarling, A.L. et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 103, 14889-14894 (2006).
5. Andersen, M.H. et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J. Immunol. 163, 3812-3818 (1999).
6. Harper, J.W. A phosphorylation-driven ubiquitination switch for cell-cycle control. Trends Cell Biol. 12, 104-107 (2002).
7. Koepp, D.M., Harper, J.W. & Elledge, S.J. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97, 431-434 (1999).
8. Reed, S.I. Ratchets and clocks: The cell cycle, ubiquitylation and protein turnover. Nat. Rev. Mol. Cell Biol. 4, 855-864 (2003).
9. Ang, X.L. & Wade Harper, J. SCF-mediated protein degradation and cell cycle control. Oncogene 24, 2860-2870 (2005).
10. Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998).
11. Wilkinson, K.D. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome. Semin. Cell Dev. Biol. 11, 141-148 (2000).
12. Princiotta, M.F. et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18, 343-354 (2003).
13. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
14. Evan, G.I. & Vousden, K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348 (2001).
15. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
16. Fecher, L.A., Cummings, S.D., Keefe, M.J. & Alani, R.M. Toward a molecular classification of melanoma, J. Clin. Oncol. 25, 1606-1620 (2007).
17. Easly, D.J. & Bennett, D.C. Protein tyrosine kinases in malignant melanoma. Melanoma Res. 10, 401-411 (2000).
18. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007).
19. Diella, F. et al. Phospho.ELM: A database of experimentally verified phosphorylation sites in eukaryotic proteins. BMC Bioinformatics 5, 79 (2004).
20. Hornbeck, P.V., Chabra, I., Kornhauser, J.M., Skrzypek, E. & Zhang, B. PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4, 1551-1561 (2004).
21. Bjorkman, P.J. et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506-512 (1987).
22. Madden, D.R., Garboczi, D.N. & Wiley, D.C. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75, 693-708 (1993).
23. Madden, D.R. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 13, 587-622 (1995).
24. Ruppert, J. et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74, 929-937 (1993).
25. Bouvier, M. & Wiley, D.C. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 265 398-402 (1994).
26. Fersht, A.R. et al. Hydrogen bonding and biological specificity analysed by protein engineering. Nature 314, 235-238 (1985).
27. Sette, A. et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586-5592 (1994).
28. Hendrickson, R.C., Skipper, J.C., Shabanowitz, J., Slingluff, C.L., Jr. & Engelhard, V.H. in Immunology Methods Manual: The Comprehensive Sourcebook of Techniques (ed. Lefkovits, I.) 605-623 (Academic, New York, 1996).
29. Martin, S.E., Shabanowitz, J., Hunt, D.F. & Marto, J.A. Subfemtomole MS and MS/MS peptide sequence analysis using nano-HPLC micro-ESI fourier transform ion cyclotron resonance mass spectrometry. Anal. Chem. 72, 4266-4274 (2000).
30. Sidney, J. et al. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum. Immunol. 62, 1200-1216 (2001).
31. Gulukota, K., Sidney, J., Sette, A. & DeLisi, C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267, 1258-1267 (1997).
32. Garboczi, D.N., Hung, D.T. & Wiley, D.C. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA 89, 3429-3433 (1992).
33. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 26, 795-800 (1993).
34. Collaborative Computational Project No 4. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Ctystallogr. 50, 760-763 (1994).
35. Brunger, A.T. et al. Crystallography & NMR system: A new software suite for macro-molecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921 (1998).
36. Brünger, A.T. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472-475 (1992).
37. Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
38. Fenn, T.D., Ringe, D. & Petsko, G.A. POVScript+: A program for model and data visualization using persistence of vision ray-tracing. J. Appl. Cryst. 36, 944-947 (2003).
39. Guex, N. & Peitsch, M.C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18, 2714-2723 (1997).
40. Nicholls, A., Sharp, K.A. & Honig, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Protein Struct. Funct. Genet. 11, 281-296 (1991).